September 2021 updates to the website
15 September 2021
The website has now been updated following September's LSCMMG
The following guidelines have been added/updated:
Vitamin D position statement- Updated
The following medicines have been added/updated:
Adalimumab, etanercept, infliximab and abatacept (NICE TA715) - for treating moderate rheumatoid arthritis after conventional DMARDs have failed
Ixekizumab (NICE TA718) - for treating axial spondyloarthritis
Secukinumab (NICE TA719) - for treating non-radiographic axial spondyloarthritis
The following Items will be updated and added to the website following the next Strategic Commissioning Committee (SCC) Meeting:
Idarucizumab - adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.